Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | 180 mg of AZD8529 |
|
| 2 | Experimental | 50 mg AD8529 |
|
| 3 | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD8529 | Drug | 6 capsules by mouth 1 time 12 to 24 prior to assessments |
|
| Measure | Description | Time Frame |
|---|---|---|
| fMRI | 3 | |
| Ketamine Infusion | 3 |
| Measure | Description | Time Frame |
|---|---|---|
| Clinician Administered Dissociative States Scale (CADSS) | ||
| Positive and Negative Syndrome Scale (PANSS) | ||
| Laboratory assessment: electrocardiogram (ECG), physical exam, vital signs, collection of adverse events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John Krystal | Chair, Department of PsychiatryYale University School of MedicineChief of Psychiatry, Yale-New Haven Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | New Haven | Connecticut | United States |
Not provided
| ID | Term |
|---|---|
| D008569 | Memory Disorders |
| ID | Term |
|---|---|
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000608263 | AZD8529 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo to match AZD8529 | Drug | 6 capsules by mouth 1 time 12 to 24 hours prior to assessments |
|
| D013568 | Pathological Conditions, Signs and Symptoms |